

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/691,117	10/21/2003	David J. Vachon	1695.003	5330	
23405 MESI INI D OT	7590 10/31/2007 HENBERG FARLEY & N	MESITI PC	EXAM	EXAMINER	
5 COLUMBIA CII	CIRCLE	WESTITIE .	BROOKS, KRI	BROOKS, KRISTIE LATRICE	
ALBANY, NY	12203		ART UNIT	PAPER NUMBER	
•			1616		
				· · · · · · · · · · · · · · · · · · ·	
		•	MAIL DATE	DELIVERY MODE	
			10/31/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•	Application No.	Applicant(s)			
Office Action Summary	10/691,117	VACHON ET AL.			
Office Action Summary	Examiner	Art Unit			
	Kristie L. Brooks	1616			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period was reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 14 Au	<u>ugust 2007</u> .				
2a) This action is FINAL . 2b) ⊠ This					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims	:				
4) Claim(s) 15-17 and 25-34 is/are pending in the 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 15-17 and 25-34 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s)/Mail Date				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal F				

Art Unit: 1616

DETAILED ACTION

Page 2

Status of Application

1. Claims 15-17 and 25-34 are pending.

- 2. New grounds of rejections.
- This action is a non-final.

Application/Control Number: 10/691,117 Page 3

Art Unit: 1616

Withdrawn Rejections/Objections

4. The objection of claims 15-17 and 25-34 for typographical errors are withdrawn in light of Applicants amendments filed August, 14, 2007.

- 5. The rejection of claims 16-17 under 35 U.S.C. 112 are withdrawn in light of Applicants amendments filed August, 14, 2007.
- 6. The rejection of claims 15-17, 31-32 under 35 U.S.C. 103(a) as being unpatentable over Laboratoire de Recherches Physiques (GB 1,098,006) in view of Blaser et al. (US 2,764,576) are withdrawn in light of Applicants amendments filed August, 14, 2007.
- 7. The rejection of claims 25-26 and 33-34 under 35 U.S.C. 103(a) as being unpatentable over Laboratoire de Recherches (GB 1,098,006) in view of Blaser et al. (US 2,764,576) are withdrawn in light of Applicants amendments filed August, 14, 2007.
- 8. The rejection of claims 27-28 under 35 U.S.C. 103(a) as being unpatentable over Laboratoire de Recherches Physiques (GB 1,098,006) in view of Blaser et al. (US 2,764,576) are withdrawn in light of Applicants amendments filed August, 14, 2007.

Art Unit: 1616

9. The rejection of claims 27-30 under 35 U.S.C. 103(a) as being unpatentable over Laboratoire de Recherches Physiques (GB 1,098,006) in view of Blaser et al. (US 2,764,576) are withdrawn in light of Applicants amendments filed August, 14, 2007.

New Grounds of Rejections

Claim Rejections - 35 USC § 102

10. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 11. Claim 15 is rejected under 35 U.S.C. 102(b) as being anticipated by Saute (US 4,126,142).

Saute teaches a skin treating formulation comprising polystyrene sulfonate salts (see the entire article, especially the abstract and column 1 lines 50-57). The sulfonated polystyrene salts are produced by sulfonating styrene monomers and treating the product with neutralizing bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide or sodium carbonate (see the entire article, especially column 1 lines 65-67 through column 2 lines 1-3). Example 1, discloses the preparation of a skin formulation comprising a polystyrene sulfonate salt and applying it to one's skin by brushing or dabbing with cotton to form an even film layer (see the entire article, especially Example 1 in column 3). It is the Examiners position with regard to the preamble, a method for controlling biological organisms on a porous surface, since the

Art Unit: 1616

method steps of the prior art and the instant invention are the same, i.e.coating a porous surface with the same polystyrene sulfonate salts, the claimed method would be inherent.

12. Claim 15, 25, and 34 are rejected under 35 U.S.C. 102(b) as being anticipated by Cohen et al. (US 2,676,896).

Cohen et al. teach the treatment of textile materials with a water-insoluble amine salt of sulfonated polystyrene (see the entire article, especially column 1 lines 1-8 and lines 27-41). The textile material include fiber, yarns, woven and knitted fabrics, apparel fabric, wool, etc (see the entire article, especially column 2 lines 35-55 and column 3 lines 1-2). The water-insoluble amine salts of sulfonated polystyrene are applied to the textile material by coating one or more sides of the textile material with the water-insoluble amine salts of sulfonated polystyrene (see the entire article, especially column 2 lines 25-34). The sulfonated polystyrene or water soluble salts thereof may be prepared using polymerization, sulfuric acid, and neutralization with bases such as quaternary ammonium hydroxides, ammonia, alkali metal hydroxides and carbonates (see the entire article, especially column 5 lines 60-75 through column 6 lines 1-13). Example I discloses cellulose actetate fabric padded through a solution of a sodium salt of sulfonated polystyrene. The dried fabric was then padded through a water solution of lauryl amine acetate where the sodium salt of sulfonated polystyrene reacted with the lauryl amine acetate to give a water-insoluble lauryl amine salt of the sulfonated polystyrene (see the entire article, especially Example I in column 6). It is the

Art Unit: 1616

Examiners position with regard to the preamble, a method for controlling biological organisms on a porous surface, since the method steps of the prior art and the instant invention are the same, i.e. coating a porous surface with the same polystyrene sulfonate salts, the claimed method would be inherent.

Claim Rejections - 35 USC § 103

- 13. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 14. Claims 16 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cohen et al. (US 2,676,896).

Applicant claims a method for controlling biological organisms on a porous

Art Unit: 1616

surface comprising forming a coating comprising a salt of a sulfonated styrene copolymer on the porous surface.

Determination of the scope and content of the prior art (MPEP 2141.01)

Cohen et al. teach the treatment of textile materials with a water-insoluble amine salt of sulfonated polystyrene (see the entire article, especially column 1 lines 1-8 and lines 27-41). The textile material include fiber, yarns, woven and knitted fabrics, apparel fabric, wool, etc (see the entire article, especially column 2 lines 35-55 and column 3 lines 1-2). The water-insoluble amine salts of sulfonated polystyrene are applied to the textile material by coating one or more sides of the textile material with the water-insoluble amine salts of sulfonated polystyrene (see the entire article, especially column 2 lines 25-34). The sulfonated polystyrene or water soluble salts thereof may be prepared using polymerization, sulfuric acid, and neutralization with bases such as quaternary ammonium hydroxides, ammonia, alkali metal hydroxides and carbonates (see the entire article, especially column 5 lines 60-75 through column 6 lines 1-13). Example I discloses cellulose actetate fabric padded through a solution of a sodium salt of sulfonated polystyrene. The dried fabric was then padded through a water solution of lauryl amine acetate where the sodium salt of sulfonated polystyrene reacted with the lauryl amine acetate to give a water-insoluble lauryl amine salt of the sulfonated polystyrene (see the entire article, especially Example I in column 6).

Art Unit: 1616

Ascertainment of the difference between the prior art and the claims (MPEP 2141.02)

Cohen al. do not teach forming a coating by coating the porous surface with the sulfonated styrene copolymer in acid form and converting the acid form of the sulfonated styrene copolymer to the salt form of the formulation as claimed by Applicant.

Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143)

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to forming a coating by coating the porous surface with the sulfonated styrene copolymer in acid form and converting the acid form of the sulfonated styrene copolymer to the salt form.

One of ordinary skill in the art would have been motivated to do this because

Cohen et al. suggest fabric padded through a solution of a sodium salt of sulfonated

polystyrene and then padded through a water solution of lauryl amine acetate where the
sodium salt of sulfonated polystyrene reacted with the lauryl amine acetate to give a

water-insoluble lauryl amine salt of the sulfonated polystyrene. Thus, it would be
obvious to one of ordinary skill in the art to coat the porous surface with the sulfonated
styrene copolymer in acid form and converting the acid form of the sulfonated styrene

Art Unit: 1616

copolymer to the salt form because it is an obvious variation of ways to coat the fabric with the polystyrene sulfonated salt and in absence of evidence to the contrary, one of ordinary skill would have employed any conventional method to coat a porous surface with the polystyrene sulfonated salt. Therefore, the claimed invention would have been

prima facie obvious to one of ordinary skill in the art at the time the invention was made

because the prior art is fairly suggestive of the claimed invention.

15. Claims 15 and 27-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berlowitz-Tarrant et al. (US 5,840,387).

Applicant claims a method for controlling biological organisms on a porous surface comprising forming a coating comprising a salt of a sulfonated styrene copolymer on the porous surface.

Determination of the scope and content of the prior art (MPEP 2141.01)

Berlowitz-Tarrant et al. teach sulfonated multiblock copolymers are useful for providing nonthrombogenic coatings for medical devices (see the entire article, especially the abstract). The nonthrombogenic article for coating includes stents, catheters, artificial hearts, heart valves, pacemakers, vascular grafts, etc. (see the entire article, especially column 1 lines 60-67). The preferred anionic multiblock copolymer is a sulfonated styrene-ethylene/butylenes-styrene triblock copolymer (see the entire article,

Art Unit: 1616

especially column 1 lines 54-57). The polymers of the present invention are useful as drug carriers for therapeutic agent such as antibiotics (see the entire article, especially column 5 lines 66-67 and column 6 lines 1-2 and 58-67).

Ascertainment of the difference between the prior art and the claims (MPEP 2141.02)

Berlowitz-Tarrant et al. do not teach forming a salt of a sulfonated styrene copolymer as claimed by Applicant.

Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143)

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to forming a salt of a sulfonated styrene copolymer.

One of ordinary skill in the art would have been motivated to do this because the salts of compounds most often provide a means to altering the physiochemical and resultant biological properties of a water insoluble compound without altering the structure. Thus it would be obvious to one of ordinary skill in the art to use a salt of a sulfonated styrene-ethylene/butylenes-styrene triblock copolymer because it allows for an improvement in the properties of the copolymer without altering the structure. Therefore, the claimed invention would have been *prima facie* obvious to one of

suggestive of the claimed invention.

Art Unit: 1616

ordinary skill in the art at the time the invention was made because the prior art is fairly

Claims 15, 17, 31 and 33-34 are rejected under 35 U.S.C. 103(a) as being 16. unpatentable over Stephenson (US 3,987, 797).

Applicant claims a method for controlling biological organisms on a porous surface comprising forming a coating comprising a salt of a sulfonated styrene copolymer on the porous surface.

Determination of the scope and content of the prior art (MPEP 2141.01)

Stephenson teaches a surgical suture coated with an ionically bonded block elastomeric copolymer of a polyquaternary polyurethane and a polyanionic polymer (see the entire article, especially the abstract. The quaternized elastomeric polymer can be reacted with anionic polymers such as polystyrene sulfonated or it alkali metal or ammonium salts (see the entire article, especially column 4 lines 29-34). The elastomeric copolymer can be used as a coating on bandages and wound dressings (see the entire article, especially column 6 lines 51-55). And the copolymer can also contain antimicrobials such as tetracycline (see the entire article, especially column 5 lines 45).

Art Unit: 1616

Ascertainment of the difference between the prior art and the claims
(MPEP 2141.02)

Stephenson does not teach an exemplification of forming a coating comprising the sulfonated polystyrene salt on a porous surface as claimed by Applicant.

Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143)

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to form a coating comprising the sulfonated polystyrene salt on a porous surface.

One of ordinary skill in the art would have been motivated to do this because the Stephenson suggests the elasotmeric polymer comprising the polystyrene sufonate salt allows for receptive treatment to antimicrobial compounds useful in coat wound dressing made for topical application. Thus it would be obvious to one of ordinary skill in the art to form a coating comprising the sulfonated polystyrene salt on a porous surface because the coating will give a more effective treatment with antimicrobial compounds. Therefore, the claimed invention would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made because the prior art is fairly suggestive of the claimed invention. Regarding the preamble, since the prior art

Art Unit: 1616

suggest the same method steps, i.e. the same polymer on a porous substrate, it is the Examiner's Position that the preamble will implicitly occur.

16. Claim 32 is rejected under 35 U.S.C. 103(a) as being unpatentable over Stephenson (US 3,987, 797) in view of Poche (US 5,932,437).

Applicant claims a method for controlling biological organisms on a porous surface comprising forming a coating comprising a salt of a sulfonated styrene copolymer on the porous surface.

Determination of the scope and content of the prior art (MPEP 2141.01)

Stephenson teaches a surgical suture coated with an ionically bonded block elastomeric copolymer of a polyquaternary polyurethane and a polyanionic polymer (see the entire article, especially the abstract. The quaternized elastomeric polymer can be reacted with anionic polymers such as polystyrene sulfonated or it alkali metal or ammonium salts (see the entire article, especially column 4 lines 29-34). The elastomeric copolymer can be used as a coating on bandages and wound dressings (see the entire article, especially column 6 lines 51-55). And the copolymer can also contain antimicrobials such as tetracycline (see the entire article, especially column 5 lines 45).

Art Unit: 1616

Poche teaches controlling lime disease by administering a composition comprising an antibiotic (see the entire article, especially the abstract). Suitable antibiotics include tetracycline and doxycycline (see the entire article, especially column 1 lines 53-60).

Ascertainment of the difference between the prior art and the claims (MPEP 2141.02)

Stephenson does not teach the instant species doxycycline as claimed by Applicant.

Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143)

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use doxycycline.

One of ordinary skill in the art would have been motivated to do this because the Stephenson suggests the use of the genus tetracycline in the wound dressings. Thus it would be obvious to one of ordinary skill in the art to use doxycycline, because it is an obvious variation of the tetracycline compounds that can be used as antibiotics as suggested by Poche. Therefore, the claimed invention would have been *prima facie*

Art Unit: 1616

obvious to one of ordinary skill in the art at the time the invention was made because the prior art is fairly suggestive of the claimed invention.

Conclusion

- 17. No claims are allowed.
- 18. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kristie L. Brooks whose telephone number is (571) 272-9072. The examiner can normally be reached on M-F 8:30am-6:00pm Est..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann R. Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ΚB

Primary Patent Examiner
Art Unit 1616